NeoGlyco Therapeutics develops dual-specificity antibodies that target unique cancer cell protein structures. Their approach aims to improve the efficacy of antibody therapies while minimizing harmful side effects by targeting previously inaccessible markers.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer therapies lack specificity, leading to off-target effects and significant toxicity in healthy tissues. Traditional antibody therapies often struggle to differentiate between cancer cells and normal cells, limiting their efficacy and causing harmful side effects. This lack of precise targeting hinders the development of more effective and less toxic cancer treatments.
Solution
NeoGlyco Therapeutics develops dual-specificity antibodies that target unique protein structures found predominantly on cancer cells. By targeting these previously inaccessible markers, their approach aims to improve the efficacy of antibody therapies while minimizing harmful side effects. These antibodies are designed to bind to cancer-specific glycans, enabling a more selective and potent anti-tumor response. This targeted approach reduces damage to healthy cells, leading to improved patient outcomes and a better quality of life during treatment. The dual-specificity design enhances binding affinity and specificity, ensuring that the therapeutic effect is concentrated on the tumor microenvironment.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics with improved safety and efficacy profiles.
Features
- Dual-specificity antibodies for enhanced targeting of cancer cells
- Focus on cancer-specific glycan targets
- Minimized off-target effects and reduced toxicity
- Improved efficacy compared to traditional antibody therapies